Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

9-13-2022

American Society of Hematology living guidelines on the use of
anticoagulation for thromboprophylaxis in patients with
COVID-19: January 2022 update on the use of therapeuticintensity anticoagulation in acutely ill patients
Adam Cuker
University of Pennsylvania

Kristen M Sanfilippo
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Cuker, Adam; Sanfilippo, Kristen M; and et al, "American Society of Hematology living guidelines on the
use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the
use of therapeutic-intensity anticoagulation in acutely ill patients." Blood Advances. 6, 17. 4915 - 4923.
(2022).
https://digitalcommons.wustl.edu/oa_4/327

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

CLINICAL GUIDELINES

American Society of Hematology living guidelines on the use of
anticoagulation for thromboprophylaxis in patients with COVID-19:
January 2022 update on the use of therapeutic-intensity anticoagulation
in acutely ill patients
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Background: COVID-19–related acute illness is associated with an increased risk of venous
thromboembolism (VTE).
Objective: These evidence-based guidelines from the American Society of Hematology (ASH) are
intended to support patients, clinicians, and other health care professionals in making decisions
about the use of anticoagulation in patients with COVID-19.
Methods: ASH formed a multidisciplinary guideline panel that included patient representatives and
applied strategies to minimize potential bias from conﬂicts of interest. The McMaster University
GRADE Centre supported the guideline development process and performed systematic evidence
reviews (through November 2021). The panel prioritized clinical questions and outcomes according
to their importance for clinicians and patients. The panel used the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach to assess evidence and make
recommendations, which were subject to public comment. This is an update to guidelines published
in February 2021 as part of the living phase of these guidelines.
Results: The panel made one additional recommendation. The panel issued a conditional
recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients
Submitted 14 March 2022; accepted 18 April 2022; prepublished online on Blood
Advances First Edition 3 May 2022; ﬁnal version published online 26 August 2022.
DOI 10.1182/bloodadvances.2022007561.
Evidence proﬁles and EtD tables are publicly available at https://guidelines.ash.
gradepro.org/proﬁle/YmZiP8YDDNA.
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with COVID-19–related acute illness who do not have suspected or conﬁrmed VTE. The panel emphasized the need for an individualized assessment of risk of thrombosis and bleeding. The panel also noted
that heparin (unfractionated or low molecular weight) may be preferred because of a preponderance of
evidence with this class of anticoagulants.
Conclusion: This conditional recommendation was based on very low certainty in the evidence,
underscoring the need for additional, high-quality, randomized controlled trials comparing different
intensities of anticoagulation in patients with COVID-19–related acute illness.

Summary of recommendations

Remarks:
 Patients with COVID-19–related acute illness are deﬁned as
those with clinical features that would typically result in admission to an inpatient medical ward without requirement for intensive clinical support. Examples include patients with dyspnea or
mild-to-moderate hypoxia.
 An individualized assessment of the patient’s risk of thrombosis
and bleeding is important when deciding on anticoagulation
intensity. Risk assessment models for estimating risk of
thrombosis in hospitalized patients have been validated in
patients with COVID-19, with modest prognostic performance.
No risk assessment models for bleeding have been validated in
patients with COVID-19. The panel acknowledges that lowerintensity anticoagulation may be preferred for patients judged to
be at high risk of bleeding and low risk of thrombosis.
 At present, there is no direct high-certainty evidence comparing
different types of anticoagulants in patients with COVID-19.
Unfractionated or low molecular weight heparin may be preferred because of a preponderance of evidence with these
agents. There are no studies of therapeutic-intensity fondaparinux, argatroban, or bivalirudin in this population.

Background
There is a high incidence of thrombotic complications in acutely ill
patients with COVID-19. Venous thromboembolism (VTE) has been
reported in up to 7.9% of such patients despite the use of standard
thromboprophylaxis.1 Thrombosis of the microvasculature contributes to other complications of COVID-19, including respiratory failure and death. At the same time, higher-intensity anticoagulation is
associated with an increased risk of bleeding among hospitalized
patients who have COVID-19.2 Consequently, there has been
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strong interest in establishing whether intensiﬁed anticoagulant regimens improve outcomes.
These guidelines are based on systematic reviews of evidence conducted under the direction of the McMaster University GRADE Centre with international collaborators. This is an update of the previous
American Society of Hematology (ASH) guideline published in February 2021,3 and it focuses on the role of anticoagulation in patients
with COVID-19–related acute illness. The panel followed best practices for guideline development recommended by the Institute of
Medicine and the Guidelines International Network (GIN).4-6 The
panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach7-13 to assess the certainty of the evidence and formulate recommendations. The
recommendation is provided in Table 1.

Values and preferences
 The guideline panel identiﬁed all-cause mortality, pulmonary
embolism (PE), deep vein thrombosis (DVT), major bleeding,
intracranial hemorrhage, ischemic stroke, ST-elevation myocardial infarction, multiple organ failure, limb amputation, invasive
mechanical ventilation, admission to the intensive care unit
(ICU), and length of hospitalization as critical outcomes and
placed a high value on avoiding these outcomes with the interventions assessed.
 Panel members noted that there was possible uncertainty and
variability in the relative value that patients place on avoiding
major bleeding events compared with reducing thrombotic
events.

Explanations and other considerations
Please refer to the original ASH guideline on thromboprophylaxis in
patients with COVID-19.3

Interpretation of strong and conditional
recommendations
Please refer to the original ASH guideline on thromboprophylaxis in
patients with COVID-19.3
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Recommendation 2b
The ASH guideline panel suggests using therapeutic-intensity
over prophylactic-intensity anticoagulation for patients with
COVID-19–related acute illness who do not have suspected
or conﬁrmed VTE or another indication for anticoagulation
(conditional recommendation based on very low certainty in
the evidence about effects ⨁
).

Introduction
Aims of this guideline and specific objectives
Please refer to the original ASH guideline on thromboprophylaxis in
patients with COVID-19.3 All recommendations and updates to
these living guidelines are accessible at the ASH COVID-19 anticoagulation webpage.14

Description of the health problem

Previously published ASH guidelines issued a conditional recommendation in favor of prophylactic-intensity rather than higher-intensity anticoagulation in patients with COVID-19–related acute illness without
suspected or conﬁrmed VTE.7 That recommendation was based on
very low certainty evidence derived exclusively from observational
studies. Since then, several randomized controlled trials (RCTs) have
been reported that compared therapeutic-intensity with prophylacticintensity anticoagulation in patients with COVID-19–related acute illness.16-20 This living guideline update incorporates evidence from
these RCTs to address the role of therapeutic-intensity vs
prophylactic-intensity anticoagulation in patients with COVID-19–
related acute illness.

Description of the target populations
The target population, patients with COVID-19–related acute illness,
is described in Table 2.

Guideline funding and management of conflicts
of interest
Supplement 3 lists all members of the guideline panel, methods
team, and systematic review team who contributed to this recommendation. Supplement 4 provides updated “Participant Information
Forms” for all panel members that contain details on ﬁnancial and
nonﬁnancial interests, as well as the ASH conﬂict-of-interest policies
agreed to by each individual. Supplement 5 provides the updated
complete “Participant Information Forms” for researchers on the
methods and systematic review teams who contributed to these
guidelines.

Formulating specific clinical questions and
determining outcomes of interest
This updated manuscript focuses on 1 question: In patients with
COVID-19–related acute illness who do not have conﬁrmed or suspected VTE, should we use direct oral anticoagulants, low molecular
weight heparin, unfractionated heparin, fondaparinux, argatroban, or
bivalirudin at therapeutic-intensity vs prophylactic-intensity? There
were no changes in the deﬁnitions for population (Table 2), anticoagulation intensity, or outcomes.21

Methods

Evidence review and development
of recommendations

This updated guideline recommendation on the use of therapeuticintensity anticoagulation in acutely ill patients was developed in the living phase of the ASH living guidelines on the use of anticoagulation
for thromboprophylaxis in patients with COVID-19 and is reported

A new Evidence-to-Decision (EtD) framework was created for Recommendation 2b (see “Recommendations”) using any applicable
evidence and information from the EtD framework for the initial Recommendation 2,7 and it was updated with new evidence and

Table 1. Recommendation
Recommendation

Remarks

Recommendation 2b. The ASH guideline panel suggests using therapeutic-intensity
over prophylactic-intensity anticoagulation for patients with COVID-19–related acute
illness who do not have suspected or conﬁrmed VTE or another indication for
anticoagulation certainty (conditional recommendation based on very low certainty in
the evidence about effects ⨁
).
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 Patients with COVID-19–related acute illness are deﬁned as those with clinical
features that would typically result in admission to an inpatient medical ward without
requirement for intensive clinical support. Examples include patients with dyspnea or
mild-to-moderate hypoxia.
 An individualized assessment of the patient’s risk of thrombosis and bleeding is
important when deciding on anticoagulation intensity. Risk assessment models for
estimating risk of thrombosis in hospitalized patients have been validated in patients
with COVID-19, with modest prognostic performance. No risk assessment models f
or bleeding have been validated in patients with COVID-19. The panel acknowledges
that lower-intensity anticoagulation may be preferred for patients judged to be at
high risk of bleeding and low risk of thrombosis.
 At present, there is no direct high-certainty evidence comparing different types of
anticoagulants in patients with COVID-19. Unfractionated or low molecular weight
heparin may be preferred because of a preponderance of evidence with these
agents. There are no studies of therapeutic-intensity fondaparinux, argatroban, or
bivalirudin in this population.
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The COVID-19 pandemic has had a signiﬁcant impact on public
health. As of 27 January 2022, more than 363 million cases and
5.6 million deaths had been attributed to COVID-19–related illness
globally.15 Thrombosis has emerged as an important complication
of patients hospitalized with COVID-19–related acute illness, with
VTEs occurring in up to 7.9% of such patients during hospitalization, often despite the use of standard thromboprophylaxis.1 Moreover, microvascular thrombosis associated with COVID-19 may
contribute to other adverse outcomes, including respiratory failure
and death.

following the RIGHT checklist (supplement 1). Living guidelines use
continuous screening for obtaining new evidence and updating analyses in living systematic reviews, a living recommendation process to
reconsider recommendations based on prespeciﬁed criteria regarding
changes in the evidence, and a living guideline panel that is continuously available to reconvene when needed (see supplement 2). The
ASH guideline panel generated Recommendation 2b on 30 November 2021, before soliciting public comments. We followed the same
methods as those published in the initial guideline,3 with the following
important updates and differences for the recommendation reported
here.

Table 2. Deﬁnition of target population
Target population
Acutely ill

Definition
Patients with COVID-19 who require hospital admission,
generally to an inpatient medical ward, without intensive
clinical support (ie, not to the ICU), but may be treated in
other settings if the hospital is over capacity. Hospital
capacity and admission criteria may vary according to the
speciﬁc setting. Some observational studies informing the
baseline risk of critical outcomes reported on all patients
hospitalized with COVID-19 in aggregate and had fewer
than 20% in the ICU without separating their outcomes.
Such populations were labeled as acutely ill.

In case of a statistically signiﬁcant difference in effects among prespeciﬁed subgroups, the Instrument for assessing the Credibility of
Effect Modiﬁcation Analyses (ICEMAN) for meta-analysis of RCTs
was completed independently by two or more evidence synthesis
team members with expertise in anticoagulation to assess whether
the credibility of the subgroup effect was high, moderate, low, or
very low.22 Finally, for all outcomes, we report pooled effect estimates based on unadjusted effects from all trials. Because 1 adaptive multiplatform trial reported adjusted effect estimates for certain
outcomes,18 we performed sensitivity analyses by pooling their
adjusted effects with the unadjusted effects of the remaining trials
to determine whether the results remained similar (see the footnotes
for the Evidence Proﬁle).

Document review

How to use these guidelines: We refer readers to the description in
the initial guideline publication from February 2021,3 and to the user
guide to ASH clinical practice guidelines.23

Recommendation
Recommendation 2b
Should direct oral anticoagulants, low molecular weight heparin,
unfractionated heparin, fondaparinux, argatroban, or bivalirudin be
prescribed at therapeutic intensity or prophylactic intensity in
patients with COVID-19–related acute illness who do not have suspected or conﬁrmed VTEs or another indication for anticoagulation?

Recommendation 2b
The ASH guideline panel suggests using therapeutic-intensity
over prophylactic-intensity anticoagulation for patients with
COVID-19–related acute illness who do not have suspected or
conﬁrmed VTE or another indication for anticoagulation (conditional recommendation based on very low certainty in the evidence about effects ⨁
).
Remarks:
 Patients with COVID-19–related acute illness are deﬁned as
those with clinical features that would typically result in admission to an inpatient medical ward without requirement for intensive clinical support. Examples include patients with dyspnea or
mild-to-moderate hypoxia.
 An individualized assessment of the patient’s risk of thrombosis
and bleeding is important when deciding on anticoagulation
intensity. Risk assessment models to estimate thrombotic risk in
hospitalized patients have been validated in patients with
COVID-19, with modest prognostic performance. No risk
assessment models for bleeding have been validated in patients
with COVID-19. The panel acknowledges that lower-intensity
anticoagulation may be preferred for patients judged to be at
high risk for bleeding and low risk for thrombosis.
 At present, there is no direct high-certainty evidence comparing
different types of anticoagulants in patients with COVID-19.
Unfractionated or low molecular weight heparin may be preferred because of a preponderance of evidence with these
agents. There are no studies of therapeutic-intensity fondaparinux, argatroban, or bivalirudin in this population.

An initial draft recommendation was reviewed by all members of the
panel and made available online from 8 October to 15 October
2021, for external review by stakeholders, including allied organizations, other medical professionals, patients, and the public. As part
of the public comment, there were 68 views; 7 individuals or organizations submitted responses. Based on the public comments and
the very low certainty of the evidence, the panel decided to review
the evidence and EtD framework judgments and draft a revised

Summary of the evidence. We rated the certainty in the evidence as moderate for the outcome of pulmonary embolism because
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considerations speciﬁcally for Recommendation 2b. The systematic
review for identifying comparative antithrombotic studies for the
entire guideline was updated until 28 November 2021, the literature
search strategy was modiﬁed only to add search terms for antiplatelet agents for another guideline question, and the protocol was modiﬁed to focus on inclusion of only RCTs for the guideline after the
initial phase. Baseline risk estimates for outcomes in patients with
COVID-19–related acute illness were updated with observational
evidence until 29 March 2021, and prophylactic-intensity anticoagulation event rates from RCTs were updated until 28 November
2021. The up-to-date protocols and search strategies for both systematic reviews are provided in supplements 6 to 9. The decision to
create this updated guideline recommendation was based on publication of several RCTs,16-20 some of which were not already
included from the systematic literature searches but were identiﬁed
by expert panel members, were critically assessed by the evidence
synthesis team, and were determined to increase the certainty of
the evidence for several critical outcomes. Decision thresholds were
obtained for each critical outcome (Table 3) to support judgments
about whether the magnitude of an effect estimate was trivial, small,
moderate, or large, as well as for determining imprecision of the
effect estimate. Thresholds were calculated by using the outcomespeciﬁc utility value and results from a decision threshold survey
that included the members of this panel.

recommendation with the new use of decision thresholds. The
revised draft recommendation was generated on 30 November
2021, and made available online from 20 December 2021 to 3 January 2022, for external review by stakeholders, including allied
organizations, other medical professionals, patients, and the public.
As part of the public comment, there were 320 views; 15 individuals
or organizations submitted responses. On 7 March 2022, the ASH
Guideline Oversight Subcommittee and the ASH Committee on
Quality veriﬁed that the deﬁned guideline development process was
followed, and on 11 March 2022, the ofﬁcers of the ASH Executive
Committee approved submission of the updated guideline manuscript for publication under the imprimatur of ASH. The updated
guideline manuscript was then subjected to peer review by Blood
Advances.

Table 3. Decision thresholds per critical outcome
Decision thresholds for No. of events per 1000 patients (95% CI)†
Outcome
Mortality

Mean utility value (SD)*
0

Trivial/small

Small/moderate

Moderate/large

31 (22-39)

60 (46-73)

0.42 (0.15)

27 (15-38)

53 (38-68)

103 (80-125)

Moderate proximal DVT

0.58 (0.14)

37 (21-53)

73 (53-94)

142 (110-173)

Major bleeding

0.33 (0.23)

23 (13-33)

46 (33-59)

89 (69-109)

Severe ischemic stroke

0.14 (0.10)

18 (10-26)

36 (26-46)

69 (54-85)

Intracranial hemorrhage

0.12 (0.10)

18 (10-25)

35 (25-45)

68 (53-83)

Multiple organ failure

0.15 (0.14)

18 (10-26)

36 (26-46)

70 (54-86)

STEMI

0.31 (0.19)

23 (13-32)

44 (32-57)

86 (67-105)

Limb amputation

0.26 (0.16)

21 (12-30)

41 (30-53)

80 (63-98)

ICU hospitalization

0.38 (0.16)

25 (14-36)

50 (36-63)

96 (75-117)

Long-term invasive ventilation

0.20 (0.12)

20 (11-28)

38 (28-49)

74 (58-91)

SD, standard deviation; STEMI, ST-elevation myocardial infarction.
*Health utility values indicate how patients would value their health state when experiencing the outcome of interest; 1.00 indicates perfect health and 0 equals death. Values were
obtained from 70 panel members from various ASH guidelines related to the management of VTE.
†A survey was administered to 151 panel members from various ASH guidelines related to the management of VTE and COVID-19, using various clinical outcome scenarios with
standardized outcome descriptors (marker states) to determine thresholds between trivial, small, moderate, and large effects for the different critical outcomes. Mortality was used as the
anchor with a utility value of 0, and the thresholds for other outcomes were determined on the basis of their utility value relative to mortality.

of serious risk of bias, moderate for major bleeding because of serious
imprecision, low for the outcomes of DVT, invasive mechanical ventilation and admission to the ICU because of serious risk of bias
and serious imprecision, and as very low for all other outcomes,
mainly because of very serious imprecision (see Evidence Proﬁle and
EtD framework online at https://guidelines.ash.gradepro.org/proﬁle/
YmZiP8YDDNA).
We found several systematic reviews of randomized controlled trials
that addressed this question, either speciﬁcally or as part of a larger
systematic review on anticoagulation in patients with COVID19.24-27 None of these systematic reviews reported a Summary of
Findings table or Evidence Proﬁle with certainty of the evidence
assessment for all critical outcomes prioritized for this recommendation. The living systematic reviews informing all recommendations for
the ASH living guidelines since June 2020 provided the evidence
for the Evidence Proﬁle and EtD framework. Supplement 10
presents the characteristics of the included studies.
Five RCTs reported the effects of therapeutic-intensity anticoagulation
in patients who were with COVID-19–related acute illness.16-20 In
the publications, or by providing unpublished data, all 5 trials reported
results for all-cause mortality, PE, DVT, major bleeding, ischemic
stroke, intracranial hemorrhage, and ST-elevation myocardial infarction. Four trials provided results for limb amputation. Three trials provided results for multiple organ failure, invasive mechanical ventilation,
and ICU admission (see Evidence Proﬁle). Three RCTs provided
unpublished data for patients who were not admitted to the ICU separately and/or for additional outcomes. In accordance with the
GRADE approach, the overall certainty of the evidence of effects was
very low based on the lowest certainty among critical outcomes.

may result in little to no difference in DVTs with 4 fewer (from 7 fewer
to 4 more) DVTs per 1000 patients (OR, 0.56; 95% CI, 0.22-1.41)
(low certainty). Therapeutic-intensity anticoagulation may result in little
to no difference in invasive mechanical ventilation with 16 fewer (from
32 fewer to 11 more) cases of invasive mechanical ventilation per
1000 patients (OR, 0.69; 95% CI, 0.39-1.22) (low certainty).
Therapeutic-intensity anticoagulation may result in little to no difference in ICU admission with 15 fewer (from 38 fewer to 17 more)
cases of invasive mechanical ventilation per 1000 patients (OR,
0.80; 95% CI, 0.52-1.23) (low certainty).
Therapeutic-intensity anticoagulation may reduce all-cause mortality
with 20 fewer (from 52 fewer to 33 more) deaths per 1000 patients
(OR, 0.78; 95% CI, 0.43-1.40), but the evidence is very uncertain
(very low certainty). We investigated whether a subgroup effect was
present for the type of anticoagulant (ie, low molecular weight heparin/unfractionated heparin vs direct oral anticoagulant) for the outcome of all-cause mortality using the ICEMAN instrument. We
found low credibility for a subgroup effect and therefore the overall
effect estimate was used, but there is remaining uncertainty. Sensitivity analysis including only the trials testing low molecular weight
heparin or unfractionated heparin showed a pooled OR of 0.60
(95% CI, 0.29-1.22), which corresponds to 36 fewer (from 66
fewer to 19 more) deaths per 1000 patients (very low certainty).

Benefits. Based on the panel’s thresholds for effect sizes (Table 3),
therapeutic-intensity anticoagulation probably results in little to no difference in PEs with 17 fewer (from 22 fewer to 9 fewer) PEs per
1000 patients (odds ratio [OR], 0.42; 95% conﬁdence interval [CI],
0.25-0.71) (moderate certainty). Therapeutic-intensity anticoagulation

Therapeutic-intensity anticoagulation may reduce multiple organ failure with 26 fewer (from 48 fewer to 208 more) cases of multiple
organ failure per 1000 patients (OR, 0.46; 95% CI, 0.03-6.59), but
the evidence is very uncertain (very low certainty). Therapeuticintensity anticoagulation may have trivial to no effect on ischemic
stroke with 0 fewer (from 3 fewer to 14 more) ischemic strokes per
1000 patients (OR, 0.92; 95% CI, 0.19-4.48), but the evidence is
very uncertain (very low certainty). Therapeutic-intensity anticoagulation may have trivial to no effect on limb amputation with 1 fewer
(from 2 fewer to 14 more) limb amputations per 1000 patients (OR,
0.33; 95% CI, 0.01-8.03), but the evidence is very uncertain (very
low certainty). Therapeutic-intensity anticoagulation may have trivial
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16 (9-22)

Moderate PE

some clinical trials. In addition, baseline risks for thrombosis-related
events were largely based on evidence collected earlier in the pandemic and it was noted that these risks may be lower in the current
phase of the pandemic.

Harms and burdens. In accordance with the panel’s thresholds
for effect sizes (Table 3), therapeutic-intensity anticoagulation probably results in little to no difference in major bleeding with 9 more
(from 0 to 26 more) major bleeding events per 1000 patients (OR,
1.79; 95% CI, 1.00-3.21) (moderate certainty). The evidence is very
uncertain about the effect of therapeutic-intensity anticoagulation on
intracranial hemorrhage (OR, 2.95; 95% CI, 0.12-72.74) as well as
the pooled mean baseline risk (0%); this corresponds to 0 more
(from 0 to 0 more) intracranial hemorrhages per 1000 patients (very
low certainty).

What are others saying, and what is new in
these guidelines?

EtD criteria and considerations. The guideline panel noted
that there was possible uncertainty and variability in the relative
value patients place on reducing thrombotic events compared
with avoiding major bleeding events. The panel agreed that the use
of therapeutic-intensity anticoagulation would be acceptable to patients and health care providers. However, given the low certainty in
the evidence for some outcomes, there may be regional variation in
the acceptability of therapeutic-intensity anticoagulation, particularly
in regions where baseline risk of VTE may be lower (eg, Asian populations).28 In addition, the panel noted possible racial and ethnic disparity in clinical trial enrollment.16-20
Conclusions. The use of decision thresholds (Table 3) allowed
the panel to quantify the magnitude of effect per outcome to come
to an overall judgment on the balance of health effects. The undesirable effects of the intervention were considered trivial, driven by a
trivial effect on major bleeding. The desirable effects of the intervention were considered small, driven by small effects on mortality and
multiorgan failure and additive trivial effects on PE, DVT, invasive
mechanical ventilation, and ICU admission. On the basis of these
judgments, the panel made a conditional recommendation for
therapeutic-intensity anticoagulation over prophylactic-intensity anticoagulation in acutely ill medical patients with COVID-19 while
acknowledging that individualized decision-making is required. The
predictive value of risk assessment models to estimate thrombotic
risk in hospitalized patients with COVID-19 has been validated29;
no risk assessment models for bleeding have been validated in this
population. Although the panel did not identify credible evidence of
a differential effect among types of anticoagulants, they noted that
unfractionated or low molecular weight heparin may be preferred
because 4 of 5 included trials used these agents.
The panel’s recommendation was not unanimous: 8 panelists voted
for a conditional recommendation in favor of therapeutic-intensity
anticoagulation, 4 panelists voted for a conditional recommendation
in favor of prophylactic-intensity anticoagulation, 4 panelists voted
for a conditional recommendation in favor of either therapeutic- or
prophylactic-intensity anticoagulation, and 3 panelists abstained,
underscoring the uncertainty in the evidence. Among panelists who
voted for a conditional recommendation in favor of prophylacticintensity anticoagulation, concerns were expressed about the potential morbidity of anticoagulant-associated major bleeding events and
possible underestimation of the absolute risk of major bleeding
because of the exclusion of patients at high risk of bleeding from
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Numerous national and international organizations have published
clinical practice guidelines or guidance documents on the role of
anticoagulation in hospitalized COVID-19 patients. Among those
published or updated since 2021 (the year that RCTs comparing
different intensities of anticoagulation were ﬁrst published), both the
Japanese living guidelines on drug management for COVID-1930
and the European Respiratory Society living guidelines31 recommend anticoagulation in patients with COVID-19–related acute illness, but they do not specify an intensity. Italian and French
guidelines suggest prophylactic-intensity anticoagulation, although
the Italian guideline notes that therapeutic-intensity anticoagulation
may be considered in patients deemed to be at high risk of thrombosis.32,33 The US National Institutes of Health COVID-19 Treatment Guideline panel recommends therapeutic-intensity heparin in
patients with COVID-19–related acute illness who have a D-dimer
level above the upper limit of normal, require low-ﬂow oxygen, and
have no increased risk of bleeding.34
Major differences between the ASH guidelines and these other
documents include use of high-quality systematic reviews and EtD
frameworks, marker states to estimate the relative importance of key
outcomes to patients, and decision thresholds to facilitate judgments about the magnitude of desirable and undesirable effects.

Limitations of this guideline
The limitations of this guideline are inherent in the low certainty of
the evidence we identiﬁed for the research question. In addition,
dramatic changes have occurred over the course of the pandemic
with respect to circulating viral variants, the affected patient population, and the use of treatments other than anticoagulants for management of COVID-19–related acute illness (eg, antiviral agents,
corticosteroids, Janus kinase inhibitors, interleukin-6 inhibitors).
Much of the evidence included in our systematic review was collected earlier in the pandemic and may not fully reﬂect baseline risk
or the impact of different intensities of anticoagulation in the current
phase of the pandemic.

Revision or adaptation of the guideline
Plans for updating the guideline
Our recommendations will continue to be updated on the basis of living reviews of evolving evidence. Our methods of living systematic
reviews and recommendations, including criteria for deciding when to
reassess and update recommendations, are described elsewhere.3

Updating or adapting recommendations locally
Adaptation of these guidelines will be necessary in many circumstances. These adaptations should be based on the associated EtD
frameworks.11
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to no effect on ST-elevation myocardial infarction with 1 fewer (from
3 fewer to 8 more) ST-elevation myocardial infarctions per 1000
patients (OR, 0.65; 95% CI, 0.14-2.97), but the evidence is very
uncertain (very low certainty).

Authorship

On the basis of gaps in evidence identiﬁed during the guideline
development process, the panel identiﬁed the following research
priorities:

Contribution: R.N., R.A.J., Y.A.J., A.M.B., A.B., M.B., R.B.-P., R.C.,
L.E.C.-L., K.D., A.J.D., H.H., S.G.K., R.M., G.P.M., R.Z.M., G.M.-S.,
M.K.N., B.A.P., Y.Q., Y.R.B., A.S., K.S., and W.W. (members of the
knowledge synthesis team) searched the literature, extracted data
from eligible studies, analyzed the data, and prepared evidence summaries and EtD tables; A.C., E.K.T., P.A., C.B., K.D., M.T.D., D.D.,
D.O.G., S.R.K., F.A.K., A.I.L., I.N., A.P., M.R., K.M.S., D.M.S., M.S.,
D.R.T., K.T., R.A.M., H.J.S. (Panel members) assessed the evidence,
voted and made judgments within the EtD framework, and discussed
and issued the recommendations; R.N., R.B.-P., K.D., A.S., K.S., A.C.,
E.A.A., W.W., R.A.M., and H.J.S. (the methods leadership team)
developed the methods and provided guidance to the knowledge
synthesis team and guideline panel; A.C., R.A.M., and H.J.S. were the
co-chairs of the panel and led panel meetings; A.C., R.N., R.A.M., and
H.J.S. wrote the manuscript; all other authors contributed to critical
revisions of the manuscript; and all authors approved of the content.

 Studies assessing baseline risk of VTE, risk of major bleeding,
and mortality in acutely ill patients receiving prophylacticintensity anticoagulation therapy and how these risks have varied
over the course of the pandemic
 Studies examining the impact of non-anticoagulant interventions (eg, vaccines, corticosteroids, antiviral therapies,
anticytokine therapies, monoclonal antibody therapies) on risk
of thrombosis
 Studies examining the impact of different viral variants on risk of
thrombosis
 Development and validation of risk assessment models for
thrombosis and bleeding in patients with COVID-19–related
acute illness
 Studies examining the impact of anticoagulant therapy on thrombosis and bleeding outcomes in patients of differing race and
ethnicity
 Studies comparing mortality, thrombosis, bleeding, and functional outcomes with different anticoagulant agents and different
dose intensities
 Studies estimating the relative disutility of thrombotic and bleeding outcomes in patients with COVID-19–related acute illness
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